Utility of Hepatitis C Viral Load Monitoring on Direct-Acting Antiviral Therapy
Clin Infect Dis June 15, 2015 V.60 N.12 P.1743-1751
Sreetha Sidharthan, Anita Kohli, Zayani Sims, Amy Nelson, Anu Osinusi, Henry Masur, and Shyam Kottilil
During hepatitis C virus (HCV) treatment with interferon-sparing direct-acting antiviral regimens, low-level quantifiable HCV RNA after completion of therapy does not preclude treatment success. Patients with detectable viremia at week 4 of treatment also have high sustained virologic response rates.
Burden of bacterial resistance among neonatal infections in low income countries: how convincing is the epidemiological evidence? Comparison of the Metabolic Effects of Ritonavir-Boosted Darunavir or Atazanavir Versus Raltegravir, and the Impact of Ritonavir Plasma Exposure: ACTG 5257